Combigan

Phase 3Small molecule

EEMS

Combigan is one of 42 small molecule programs targeting Ocular Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ocular HypertensionActive, not recruiting

Diabetic Macular EdemaActive, not recruiting

Ocular HypertensionPhase 3

Active, not recruiting

Diabetic Macular EdemaPreclinical

Active, not recruiting

Competition

Competitive Landscape

187 competitors in Ocular Hypertension

#DrugCompanyPhaseTrials

Alphagan

Novartis

Phase 3

1 2

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

9 3

Comparator: Pbo

Merck & Co.

Phase 3

2 4

Azopt

Novartis

Phase 3

1 5

Ocupress

AbbVie

Phase 3

1 6

LUMIGAN

AbbVie

Phase 3

2 7

Krytantek

AbbVie

Phase 3

2 8

Bimatoprost/timolol

AbbVie

Phase 3

4 9

Preservative-Free Tafluprost

Merck & Co.

Phase 3

2 10

Combigan

EEMS

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prophylaxis1 trial

Prophylaxis for Anti-VEGF-induced IOP Elevation

Withdrawn·MMcMaster University·N/A·NCT02623023

Diabetic Macular Edema1 trial

The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema

Unknown status·MMeir Medical Center·N/A·NCT02718547·25 enrolled

Treatment1 trial

The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter

Unknown status·—·Phase 2·NCT02214680·25 enrolled

Ocular Hypertension1 trial

BREMEN Eye Drops Versus Combigan for Open-angle Glaucoma or Intraocular Hypertension

Completed·EEMS·Phase 3·NCT03235232·406 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Combigan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Combigan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Combigan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EMS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEMS

Combigan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prophylaxis1 trial

Diabetic Macular Edema1 trial

Treatment1 trial

Ocular Hypertension1 trial

References

Drug Info

Quick Facts

Related News